Baltimore sues Biogen, saying the company colluded with PBMs to minimize generic competition

Baltimore’s mayor and city council have sued Biogen, alleging that the Boston-based drug developer worked with pharmacy benefit managers to suppress generic versions of a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard – Biotech Investments

EQS-News: M1 Kliniken AG / Key word(s): Investment Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting

February 6, 2024

After years of delay, BeiGene finally lands FDA approval for its PD-1 drug

BeiGene has won the first FDA approval for its PD-1 inhibitor, marking a hard-earned milestone after a winding regulatory journey that began two and a

March 16, 2024

Congress Making Progress on Bills to Regulate PBMs

Confused by all the bills being introduced in Congress to regulate pharmacy benefit managers (PBMs)? You’re not alone. Not only is the Senate Finance Committee

August 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.